STUDY OBJECTIVE: To determine whether the methacholine challenge method used for albuterol can be applied to assess long-acting β2-adrenergic agonist (LABA) bioequivalence, which would require a sufficiently steep dose-response curve. DESIGN: Prospective, unblinded, randomized, 2-way crossover study. SETTING: University medical center clinical research laboratory. PATIENTS: Ten adults, aged 21-58 years, with mild asthma (forced expiratory volume in 1 sec [FEV(1)] ≥ 70% predicted) and a baseline provocational concentration of methacholine required to decrease FEV(1) by 20% (PC(20)) of 4 mg/ml or less completed the study. INTERVENTION: Patients were randomized to receive a single dose of either 12 or 24 μg of formoterol delivered by a dry powder inhaler; 3-7 days later, at the same time of day, they received the other dose. MEASUREMENTS AND MAIN RESULTS: The FEV(1) was measured before and 1 hour after dosing, followed by performance of a methacholine challenge. Statistical analysis was performed by the 2-sample regression method for crossover studies. The dose-response curve for bronchodilatation was flat; the mean ± SD increase in FEV(1) after formoterol 12 and 24 μg was 14 ± 5% and 14 ± 8%, respectively (p>0.05). In contrast, the geometric mean PC20 (95% confidence interval) was 7 mg/ml (2-22 mg/ml) after the 12-μg dose and 16 mg/ml (5-45 mg/ml) after the 24-μg dose (p<0.001). CONCLUSION: Bioassay by methacholine challenge will be useful for bioequivalence studies of LABAs. A sample of at least 28 patients will be required for formoterol when methacholine challenge is performed in an optimal manner. The sample size may differ for other LABAs.
RCT Entities:
STUDY OBJECTIVE: To determine whether the methacholine challenge method used for albuterol can be applied to assess long-acting β2-adrenergic agonist (LABA) bioequivalence, which would require a sufficiently steep dose-response curve. DESIGN: Prospective, unblinded, randomized, 2-way crossover study. SETTING: University medical center clinical research laboratory. PATIENTS: Ten adults, aged 21-58 years, with mild asthma (forced expiratory volume in 1 sec [FEV(1)] ≥ 70% predicted) and a baseline provocational concentration of methacholine required to decrease FEV(1) by 20% (PC(20)) of 4 mg/ml or less completed the study. INTERVENTION: Patients were randomized to receive a single dose of either 12 or 24 μg of formoterol delivered by a dry powder inhaler; 3-7 days later, at the same time of day, they received the other dose. MEASUREMENTS AND MAIN RESULTS: The FEV(1) was measured before and 1 hour after dosing, followed by performance of a methacholine challenge. Statistical analysis was performed by the 2-sample regression method for crossover studies. The dose-response curve for bronchodilatation was flat; the mean ± SD increase in FEV(1) after formoterol 12 and 24 μg was 14 ± 5% and 14 ± 8%, respectively (p>0.05). In contrast, the geometric mean PC20 (95% confidence interval) was 7 mg/ml (2-22 mg/ml) after the 12-μg dose and 16 mg/ml (5-45 mg/ml) after the 24-μg dose (p<0.001). CONCLUSION: Bioassay by methacholine challenge will be useful for bioequivalence studies of LABAs. A sample of at least 28 patients will be required for formoterol when methacholine challenge is performed in an optimal manner. The sample size may differ for other LABAs.
Authors: R O Crapo; R Casaburi; A L Coates; P L Enright; J L Hankinson; C G Irvin; N R MacIntyre; R T McKay; J S Wanger; S D Anderson; D W Cockcroft; J E Fish; P J Sterk Journal: Am J Respir Crit Care Med Date: 2000-01 Impact factor: 21.405
Authors: Wallace P Adams; Richard C Ahrens; Mei-Ling Chen; David Christopher; Badrul A Chowdhury; Dale P Conner; Richard Dalby; Kevin Fitzgerald; Leslie Hendeles; Anthony J Hickey; Günther Hochhaus; Beth L Laube; Paul Lucas; Sau L Lee; Svetlana Lyapustina; Bing Li; Dennis O'Connor; Neil Parikh; David A Parkins; Prasad Peri; Gary R Pitcairn; Michael Riebe; Partha Roy; Tushar Shah; Gur Jai Pal Singh; Sandra Suarez Sharp; Julie D Suman; Marjolein Weda; Janet Woodcock; Lawrence Yu Journal: J Aerosol Med Pulm Drug Deliv Date: 2010-02 Impact factor: 2.849
Authors: Peter S Creticos; Wallace P Adams; Brent G Petty; Lionel D Lewis; Gur Jai Pal Singh; Arouna P Khattignavong; Justina A Molzon; Marilyn N Martinez; Paul S Lietman; Roger L Williams Journal: J Allergy Clin Immunol Date: 2002-11 Impact factor: 10.793
Authors: Leslie Hendeles; Peter T Daley-Yates; Robert Hermann; Jan De Backer; Sanjeeva Dissanayake; Stephen T Horhota Journal: AAPS J Date: 2015-02-26 Impact factor: 4.009